Drug-resistant tuberculosis kills around 250,000 people every year.
The report identified a dozen other priority classes of pathogen, including those causing common infections such as pneumonia or UTIs, which are becoming "increasingly resistant to existing antibiotics and urgently in need of new treatments".
As of now, the report titled, Antibacterial agents in clinical development, says about 51 new antibiotics are being developed to possibly treat antibiotic-resistant pathogens. This happens with genetic changes in viruses, misuse or mistreatment of antibiotics and antibiotics that kill viruses, giving the super viruses more space the grow and spread.
Despite a recent multinational initiatives like the €56m Global Antibiotic Research and Development Partnership, WHO said that new drugs will not completely solve the problem and is encouraging greater procedures for the prevention of infection.
The WHO warned however that new treatments alone would not be sufficient and stressed the importance of responsible use of antibiotics in people and animals.
There aren't enough truly new antibiotics being developed, especially for the most concerning antibiotic-resistant infections, according to a World Health Organization report released Tuesday... But the World Health Organization said that only eight of these are deemed to be innovative treatments that will add value to the current antibiotic treatment arsenal. The report also says that few of these are oral antibiotics, which are better for wider access outside of hospital settings.
Researchers are working on new antibiotics, but so far, few are good enough to add to the existing antibiotic treatment stockpiles. But only two new antibiotics for the disease have reached the market in 70 years.
Ed Whiting, director of policy at the Wellcome Trust, added: 'There is no doubt of the urgency - the world is running out of effective antibiotics and drug-resistant infections already kill 700,000 people a year globally. But now, a year on from a major United Nations agreement, we must see concerted action - to reinvigorate the antibiotic pipeline, ensure responsible use of existing antibiotics, and address this threat across human, animal and environmental health.